title: Etoricoxib-induced toxic epidermal necrolysis: successful treatment with infliximab.
authors.forename: Burkhard
authors.initials: B
authors.lastname: Kreft
authors.forename: Johannes
authors.initials: J
authors.lastname: Wohlrab
authors.forename: Isa
authors.initials: I
authors.lastname: Bramsiepe
authors.forename: Regina
authors.initials: R
authors.lastname: Eismann
authors.forename: Matthias
authors.initials: M
authors.lastname: Winkler
authors.forename: Wolfgang Christian
authors.initials: WC
authors.lastname: Marsch
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects; D003879:Dermatologic Agents / Q000627:therapeutic use*; D000077613:Etoricoxib; D006801:Humans; D000069285:Infliximab; D008297:Male; D011725:Pyridines / Q000009:adverse effects; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy* / Q000209:etiology; D013450:Sulfones / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D052246:Cyclooxygenase 2 Inhibitors; D003879:Dermatologic Agents; D011725:Pyridines; D013450:Sulfones; D000069285:Infliximab; D000077613:Etoricoxib